Background: Biosimilar biological disease modifying anti-rheumatic drugs (B-bDMARDs) are a cost-effective treatment for autoimmune rheumatic diseases (ARDs). Despite current guidelines [3] consider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback